Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.95 |
| ▸ | HPGD | P15428 | 5/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.95 |
| ▸ | TSHR | P16473 | 2/20 | 0.95 |
| ▸ | MAPT | P10636 | 1/20 | 0.95 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylamide SCHEMBL29384763 | 0.97 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL21646 | 0.97 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL27497234 | 0.97 | KDM4E (1.00) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL11412975 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL18729462 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL7198790 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL723112 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL11599751 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL30995449 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR | |
| Salicylamide SCHEMBL4949313 | 0.95 | KDM4E (0.95) | KDM4EHPGDALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 740 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250256009-A1 | DECELLULARIZED BIOMATERIAL FROM NON-MAMMALIAN TISSUE | NEXTGEN BIOLOGICS, INC. (US) | 2025-08-14 | — | — | US | claimed |
| CN-114634461-B | Card Sha Lan synthesis process and reaction kettle thereof | 安徽兴东化工有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-114634461-A | Kazalan synthesis process and reaction kettle thereof | 安徽兴东化工有限公司 | 2022-06-17 | — | — | CN | claimed |
| CN-106259422-B | A kind of auxiliary agent and preparation method thereof for micro-capsule suspension | 威尔（福建）生物有限公司 | 2018-09-25 | — | — | CN | claimed |
| CN-106259422-A | A kind of auxiliary agent for micro-capsule suspension and preparation method thereof | 威尔（福建）生物有限公司 | 2017-01-04 | — | — | CN | claimed |
| US-8029822-B2 | Controlled release of active material contained in core; passageway; rupturable walls; osmosis | Osmotica Kereskedelmi és Seolgáltató KFT (HU) | 2011-10-04 | — | — | US | claimed |
| EP-1732591-A2 | COMBINED IMMUNOTHERAPY OF FUSION CELLS AND INTERLEUKIN-12 FOR TREATMENT OF CANCER | OHNO, Tsuneya (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2005079271-A2 | COMBINED IMMUNOTHERAPY OF FUSION CELLS AND INTERLEUKIN-12 FOR TREATMENT OF CANCER | OHNO TSUNEYA (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050180951-A1 | Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer | OHNO TSUNEYA (US) | 2005-08-18 | — | — | US | claimed |
| US-20050008702-A1 | Rupturing controlled release device having a preformed passageway | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2005-01-13 | — | — | US | claimed |
| US-20040028663-A1 | Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer | OHNO TSUNEYA (US) | 2004-02-12 | — | — | US | claimed |
| EP-3600160-B1 | MANDREL-LESS ELECTROSPINNING PROCESSING METHOD AND SYSTEM, AND USES THEREFOR | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12576192-B2 | Multi-layered graft for tissue engineering applications | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-03-17 | — | — | US | disclosed |
| US-12564492-B2 | Retrievable self-expanding non-thrombogenic low-profile percutaneous atrioventricular valve prosthesis | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-03-03 | — | — | US | disclosed |
| US-12521235-B2 | Stentless biopolymer heart valve replacement capable of living tissue regeneration | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-01-13 | — | — | US | disclosed |
| US-3964482-A | Drug delivery device | ALZA CORPORATION (US) | 1976-06-22 | — | — | US | disclosed |
| US-3950521-A | ANALGESIC, ANTIINFLAMMATORY, ANTIPYRETIC, SEDATIVE | INTERX RESEARCH CORPORATION (US) | 1976-04-13 | — | — | US | disclosed |
| US-3948254-A | Novel drug delivery device | ALZA CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
| US-3948262-A | Novel drug delivery device | ALZA CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
| US-3944064-A | Self-monitored device for releasing agent at functional rate | ALZA CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564492-B2 | Retrievable self-expanding non-thrombogenic low-profile percutaneous atrioventricular valve prosthesis | SEPTIN6, BMP6, BMP2 | KDM4E 3425/4885HPGD 2398/4885ALDH1A1 4582/4885 |
| US-12576192-B2 | Multi-layered graft for tissue engineering applications | MSTN, TNNT2, MEF2D | KDM4E 836/4885HPGD 309/4885ALDH1A1 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.